A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.

Target Oncol · 2017 · PMC5447332 · PMID 28357727

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Moreover, pharmacodynamics (PD) analyses using patient-derived mononuclear cells from day 1 (pre-treatment) and 28 (post-treatment) in six patients showed a trend towards decreased phosphorylation of 4E-BP1, a downstream substrate of mTOR (data not shown).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.